[go: up one dir, main page]

AU2001236207A1 - Powder formulation - Google Patents

Powder formulation

Info

Publication number
AU2001236207A1
AU2001236207A1 AU2001236207A AU3620701A AU2001236207A1 AU 2001236207 A1 AU2001236207 A1 AU 2001236207A1 AU 2001236207 A AU2001236207 A AU 2001236207A AU 3620701 A AU3620701 A AU 3620701A AU 2001236207 A1 AU2001236207 A1 AU 2001236207A1
Authority
AU
Australia
Prior art keywords
powder formulation
excipient
particle size
size distribution
active substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001236207A
Inventor
Anne Haaije De Boer
Henderik Willem Frijlink
Hendrikus Gerardus Maria Heijerman
Petrus Paulus Hendricus Le Brun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rijksuniversiteit Groningen
Original Assignee
Rijksuniversiteit Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8171037&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001236207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rijksuniversiteit Groningen filed Critical Rijksuniversiteit Groningen
Publication of AU2001236207A1 publication Critical patent/AU2001236207A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2206/00—Characteristics of a physical parameter; associated device therefor
    • A61M2206/10—Flow characteristics
    • A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a powder formulation for administration by inhalation comprising an active substance and a pharmaceutically acceptable excipient, which composition has the form of a physical mixture and comprises from 5 to 25 wt.% of the excipient, and wherein the active substance has a particle size distribution of from 0.5 to 10 mu m, and wherein the excipient has a particle size distribution of from 15 to 500 mu m.
AU2001236207A 2000-02-17 2001-02-19 Powder formulation Abandoned AU2001236207A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200550A EP1129705A1 (en) 2000-02-17 2000-02-17 Powder formulation for inhalation
EP00200550 2000-02-17
PCT/NL2001/000133 WO2001060341A1 (en) 2000-02-17 2001-02-19 Powder formulation

Publications (1)

Publication Number Publication Date
AU2001236207A1 true AU2001236207A1 (en) 2001-08-27

Family

ID=8171037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001236207A Abandoned AU2001236207A1 (en) 2000-02-17 2001-02-19 Powder formulation

Country Status (7)

Country Link
US (1) US7344734B2 (en)
EP (2) EP1129705A1 (en)
AT (1) ATE271383T1 (en)
AU (1) AU2001236207A1 (en)
DE (1) DE60104399T2 (en)
PT (1) PT1257260E (en)
WO (1) WO2001060341A1 (en)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE294608T1 (en) 1999-06-05 2005-05-15 Innovata Biomed Ltd MEDICINE ADMINISTRATION SYSTEM
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9920839D0 (en) 1999-09-04 1999-11-10 Innovata Biomed Ltd Inhaler
AR028746A1 (en) 2000-06-23 2003-05-21 Norton Health Care Ltd DOSE CARTRIDGE PREVIOUSLY MEASURES FOR DRY POWDER INHALER OPERATED BY BREATHING, INHALER AND A METHOD OF PROVISION OF DOSE PREVIOUSLY DRY POWDER MEASURES
US6681768B2 (en) 2001-06-22 2004-01-27 Sofotec Gmbh & Co. Kg Powder formulation disintegrating system and method for dry powder inhalers
DE10129703A1 (en) * 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Atomizing system for a powder mixture and method for dry powder inhalers
GB0128148D0 (en) 2001-11-23 2002-01-16 Innovata Biomed Ltd Assembly
AU2003220125B2 (en) 2002-03-20 2006-06-15 Mannkind Corporation Inhalation apparatus
AU2003215347A1 (en) 2002-04-19 2003-11-03 3M Innovative Properties Company A spacer for inertial removal of the non-respirable fraction of medicinal aerosols
CN1694689A (en) * 2002-09-30 2005-11-09 阿库斯菲尔公司 Slow-release porous microparticles for inhalation
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1488819A1 (en) 2003-06-16 2004-12-22 Rijksuniversiteit te Groningen Dry powder inhaler and method for pulmonary inhalation of dry powder
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CA2533887A1 (en) * 2003-09-30 2005-04-14 Acusphere, Inc. Injectable, oral, or topical sustained release pharmaceutical formulations
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
WO2005102429A1 (en) 2004-04-21 2005-11-03 Innovata Biomed Limited Inhaler
GB0409197D0 (en) 2004-04-24 2004-05-26 Innovata Biomed Ltd Device
SE530006C2 (en) * 2004-06-18 2008-02-05 Mederio Ag Inhaler using tub
PL1786784T3 (en) 2004-08-20 2011-04-29 Mannkind Corp Catalysis of diketopiperazine synthesis
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
AU2006272438B2 (en) 2005-07-15 2011-08-04 Map Pharmaceuticals, Inc. Method of particle formation
AU2006290870B2 (en) 2005-09-14 2013-02-28 Mannkind Corporation Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
JP2009519970A (en) * 2005-12-15 2009-05-21 アキュスフィア， インコーポレイテッド Process for producing particle-based pharmaceutical dosage forms for oral administration
DK1986679T3 (en) 2006-02-22 2017-11-20 Mannkind Corp PROCEDURE FOR IMPROVING THE PHARMACEUTICAL PROPERTIES OF MICROPARTICLES INCLUDING DICETOPIPERAZINE AND AN ACTIVE INGREDIENT
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP2176251B1 (en) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
EP2020249A1 (en) * 2007-08-01 2009-02-04 Boehringer Ingelheim Pharma GmbH & Co. KG Inhalator
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
HUE027246T2 (en) 2008-01-24 2016-10-28 Vectura Delivery Devices Ltd Inhaler
US8485180B2 (en) * 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN103252007B (en) 2008-06-13 2016-06-22 曼金德公司 Diskus and the system for medicine conveying
JP5479465B2 (en) 2008-06-20 2014-04-23 マンカインド コーポレイション Interactive device and method for profiling inhalation efforts in real time
TWI614024B (en) 2008-08-11 2018-02-11 曼凱公司 Ultra-fast use of insulin
GB0818476D0 (en) * 2008-10-09 2008-11-12 Vectura Delivery Device Ltd Inhaler
GB201020130D0 (en) * 2010-11-26 2011-01-12 Vectura Delivery Devices Ltd Inhaler
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
WO2010060876A1 (en) * 2008-11-28 2010-06-03 Boehringer Ingelheim International Gmbh Dispersion method for determining particle adhesion force
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102361876B (en) 2009-01-26 2015-02-04 以色列生物研究所 Bicyclic heterocyclic spiro compounds
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR101875969B1 (en) 2009-06-12 2018-07-06 맨카인드 코포레이션 Diketopiperazine microparticles with defined specific surface areas
DE102009037840B4 (en) * 2009-08-18 2012-08-16 Gamptec Gmbh Inhalation device and method for inhaling an active ingredient from a capsule
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
GB0919465D0 (en) * 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
RU2531455C2 (en) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Systems and methods for dry powder drugs delivery
CN105667994B (en) 2011-04-01 2018-04-06 曼金德公司 Blister package for pharmaceutical kit
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013063160A1 (en) 2011-10-24 2013-05-02 Mannkind Corporation Methods and compositions for treating pain
SG11201500218VA (en) 2012-07-12 2015-03-30 Mannkind Corp Dry powder drug delivery systems and methods
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP2970149B1 (en) 2013-03-15 2019-08-21 MannKind Corporation Microcrystalline diketopiperazine compositions and methods
EP3017823B1 (en) 2013-07-03 2019-02-20 Biopraxis Research AIE Lipid nanoparticle of polymyxin
CN105451716A (en) 2013-07-18 2016-03-30 曼金德公司 Thermally stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
SG11201700621XA (en) 2014-07-25 2017-02-27 Agency Science Tech & Res Antibiotic compositions for treating bacterial infections
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
WO2019183245A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
AU2019419414A1 (en) 2018-12-31 2023-04-06 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US12029709B2 (en) 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
US5048227A (en) * 1988-05-05 1991-09-17 Junya Okubo Method of cultivating agaricus blazei mushroom
DE4140689B4 (en) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
DE4211475A1 (en) * 1991-12-14 1993-06-17 Asta Medica Ag POWDER INHALATOR
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
ATE202481T1 (en) * 1996-11-15 2001-07-15 Pathogenesis Corp PURE, BIOLOGICALLY ACTIVE COLISTINE, ITS COMPONENTS AND A COLISTINE PREPARATION FOR THE TREATMENT OF RESPIRATORY INFLAMMATION
GB9626263D0 (en) * 1996-12-18 1997-02-05 Innovata Biomed Ltd Powder inhaler
JP3051073B2 (en) * 1996-12-20 2000-06-12 住友林業株式会社 Antitumor active substance
SE9700133D0 (en) 1997-01-20 1997-01-20 Astra Ab New formulation
AU5879298A (en) * 1997-02-12 1998-09-08 Imb Kabushiki Gaisha Method of cultivating fruit bodies of (agaricus blazei) in artificial mushroom cultivation bed
US6465218B1 (en) * 1997-04-08 2002-10-15 Japan Applied Microbiology Research Institute Co., Ltd. Biologically active substance and process of preparing the same
EP0876814A1 (en) 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
US5980918A (en) * 1997-10-24 1999-11-09 Brennen Medical, Inc. β-D-glucan topical composition
GB9820746D0 (en) * 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US6120772A (en) * 1998-10-08 2000-09-19 Hitoshi Ito Oral drugs for treating AIDS patients

Also Published As

Publication number Publication date
EP1257260B1 (en) 2004-07-21
US20030053960A1 (en) 2003-03-20
WO2001060341A1 (en) 2001-08-23
EP1257260A1 (en) 2002-11-20
DE60104399T2 (en) 2005-09-08
ATE271383T1 (en) 2004-08-15
DE60104399D1 (en) 2004-08-26
PT1257260E (en) 2004-12-31
US7344734B2 (en) 2008-03-18
EP1129705A1 (en) 2001-09-05

Similar Documents

Publication Publication Date Title
AU2001236207A1 (en) Powder formulation
IL114596A0 (en) Pharmaceutical compositions for administration by inhalation
AU2002316820A1 (en) Powder inhaler formulations
EP1312357A3 (en) Pharmaceutical formulations for dry powder inhalers
YU68199A (en) Pharmaceutical formulations containing voriconazole
MXPA04007427A (en) Dry granulated formulations of azithromycin.
AU5677099A (en) New solid dose form of nanoparticulate naproxen
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
WO2000007979A3 (en) Compounds and compositions for delivering active agents
CA2385890A1 (en) Controlled release compositions comprising nimesulide
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
MY127350A (en) Flash-melt oral dose formulations
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2002100338A3 (en) Compound and composition for delivering active agents
WO2004017942A8 (en) Inhalation compositions with high drug ratios
YU72802A (en) Pharmaceutical compositions containing oligosaccharides and preparation thereof
BE2016C017I2 (en)
WO1999058527A3 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
WO2002041879A3 (en) Antidiabetic compositions containing a biguanide and a sulfonamide
WO2002020056A3 (en) Methods and compositions for producing a neurosalutary effect in a subject
WO2001053322A3 (en) Aerothricin analogs, their preparation and use
WO2005087192A3 (en) Salmeterol inhalation formulations